The estimated Net Worth of Stephen S Phd Tang is at least $2.83 Millón dollars as of 14 May 2019. Stephen Tang owns over 1,000 units of Orasure Technologies stock worth over $509,830 and over the last 14 years he sold OSUR stock worth over $205,279. In addition, he makes $2,114,820 as President, Chief Executive Officer y Director at Orasure Technologies.
Sign up
Stephen Tang OSUR stock SEC Form 4 insiders trading
Stephen has made over 7 trades of the Orasure Technologies stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of OSUR stock worth $8,560 on 14 May 2019.
The largest trade he's ever made was exercising 40,000 units of Orasure Technologies stock on 15 February 2017 worth over $328,400. On average, Stephen trades about 3,998 units every 33 days since 2011. As of 14 May 2019 he still owns at least 119,960 units of Orasure Technologies stock.
You can see the complete history of Stephen Tang stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Tang biography
Dr. Stephen S. Tang Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Tang has served as President and Chief Executive Officer of The University City Science Center, an urban research park and business incubator owned by over thirty leading universities, medical schools and health networks in the greater Philadelphia, Pennsylvania area. Prior to that, Dr. Tang held senior management and business development positions with several firms in the life sciences industry, including Olympus America, Inc., Millennium Cell Inc. and A.T. Kearney Inc. Dr. Tang holds a B.S. degree in Chemistry from The College of William and Mary, an M.S. degree and Ph.D. in Chemical Engineering from Lehigh University and an MBA from The Wharton School of Business at the University of Pennsylvania.
What is the salary of Stephen Tang?
As the President, Chief Executive Officer y Director of Orasure Technologies, the total compensation of Stephen Tang at Orasure Technologies is $2,114,820. There are no executives at Orasure Technologies getting paid more.
How old is Stephen Tang?
Stephen Tang is 59, he's been the President, Chief Executive Officer y Director of Orasure Technologies since 2018. There are 6 older and 12 younger executives at Orasure Technologies. The oldest executive at Orasure Technologies Inc. is Ronny Lancaster, 68, who is the Independent Director.
What's Stephen Tang's mailing address?
Stephen's mailing address filed with the SEC is 220 EAST FIRST STREET, , BETHLEHEM, PA, 18015.
Insiders trading at Orasure Technologies
Over the last 21 years, insiders at Orasure Technologies have traded over $21,897,384 worth of Orasure Technologies stock and bought 196,200 units worth $1,037,188 . The most active insiders traders include Douglas A Michels, Ronald H Spair y Michael J Gausling. On average, Orasure Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $221,123. The most recent stock trade was executed by Kathleen Gallagher Weber on 19 December 2023, trading 24,129 units of OSUR stock currently worth $194,238.
What does Orasure Technologies do?
based in bethlehem, pennsylvania, orasure technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. these products include tests for the detection of antibodies to the hiv virus, including the oraquick® in-home hiv test, oraquick advance® rapid hiv-1/2 antibody test and the orasure® hiv-1 oral specimen collection device, a test for antibodies to the hcv virus, the oraquick® hcv rapid antibody test, and oral fluid testing solutions for drugs of abuse testing, including intercept® oral fluid drug testing system and q.e.d.® saliva alcohol test. orasure also manufactures and sells several leading cryosurgical products. these include: histofreezer®, a product for the cryosurgical removal of common and plantar warts and several other benign skin lesions, sold to the professional or physician office market, as well as an over-the-counter product fo
What does Orasure Technologies's logo look like?
Complete history of Stephen Tang stock trades at Orasure Technologies
Orasure Technologies executives and stock owners
Orasure Technologies executives and other stock owners filed with the SEC include:
-
Stephen Tang,
President, Chief Executive Officer, Director -
Dr. Stephen S. Tang,
Pres, CEO & Director -
Roberto Cuca,
Chief Financial Officer -
Kathleen Gallagher Weber,
Exec. VP & Bus. Unit Leader of Molecular Solutions -
Jack Jerrett,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Kathleen Weber,
Executive Vice President, Business Unit Leader, Molecular Solutions at DNAG -
Scott Gleason,
Sr. VP of Investor Relations & Corp. Communications and Interim CFO -
Michael Celano,
Independent Chairman of the Board -
Ronny Lancaster,
Independent Director -
Eamonn Hobbs,
Independent Director -
Mara Aspinall,
Independent Director -
James Datin,
Independent Director -
David Shulkin,
Independent Director -
Lelio Marmora,
Director -
Michele Miller,
Vice President - Finance, Controller, Assistant Secretary -
Lisa Nibauer,
Executive Vice President, Business Unit Leader, Infectious Disease -
Amy Steigerwalt,
VP of HR -
David A. Rappaport C.F.A., CFA,
Sr. VP Corp. Devel., Strategy & Integration -
Carrie Eglinton Manner,
Pres, CEO & Director -
Michele Marie Miller,
VP of Fin., Controller & Assistant Sec. -
Agnieszka M. Gallagher J.D.,
Gen. Counsel, Chief Compliance Officer & Sec. -
Lisa Nibauer,
Pres of Diagnostics -
Jeanne Mell,
VP of Corp. Communications -
Michele Marie Anthony,
SVP Finance & CAO -
Douglas G Watson,
Director -
Mark L Kuna,
VP & Controller -
Roger L Pringle,
Director -
Michael Reed,
SVP R&D and CSO -
Ronald H Spair,
Exec. VP & CFO -
Douglas A Michels,
President and CEO -
Brian Smith,
EVP & BU Lead - Molecular -
Nancy J Gagliano,
Director -
Gregory B Lawless,
Director -
Aradhana Sarin,
Director -
Gerald M Ostrov,
Director -
Eric Whitters,
SVP, Research and Development -
Stephen R Lee,
EVP & Chief Science Officer -
P Michael Formica,
Exec. VP - Operations -
Michael J Gausling,
President & CEO -
Joseph E Zack,
Exec. VP, Marketing & Sales -
Manuel O. Mendez,
VP, Marketing and Sales -
Frank G Hausmann,
Director -
Jack Goldstein,
Director -
Carter H Eckert,
Director -
Ii Anthony Zezzo,
EVP & BU Lead - Infectious -
Charles W Patrick,
Director -
John P. Kenny,
Director -
Robert W. Mc Mahon,
Director -
Agnieszka Gallagher,
General Counsel & CCO -
Scott Gleason,
Interim CFO/SVP IR -
Anne Clem Whitaker,
Director -
Manner Carrie Eglinton,
President & CEO -
Kenneth J Mc Grath,
Chief Financial Officer